Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Moderate Buy" from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $52.00.

A number of equities research analysts recently commented on the company. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Raymond James reaffirmed an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Leerink Partnrs cut shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the company's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company's stock, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AGIO. Farallon Capital Management LLC boosted its stake in Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company's stock valued at $163,469,000 after acquiring an additional 1,423,000 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company's stock worth $48,887,000 after buying an additional 855,739 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company's stock worth $58,861,000 after acquiring an additional 388,381 shares during the period. Frazier Life Sciences Management L.P. grew its stake in Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company's stock valued at $37,600,000 after purchasing an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at about $13,922,000.

Agios Pharmaceuticals Stock Down 0.6 %

AGIO stock traded down $0.28 during midday trading on Tuesday, hitting $45.38. The company's stock had a trading volume of 343,330 shares, compared to its average volume of 699,662. Agios Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $53.28. The company has a 50 day moving average of $44.64 and a two-hundred day moving average of $41.29. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -7.18 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. Agios Pharmaceuticals's revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.51) EPS. On average, analysts anticipate that Agios Pharmaceuticals will post -4.87 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.